These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11012098)

  • 1. Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis.
    Giannini E; Borro P; Botta F; Chiarbonello B; Fasoli A; Malfatti F; Romagnoli P; Testa E; Risso D; Lantieri PB; Antonucci A; Boccato M; Milone S; Testa R
    Int J Biol Markers; 2000; 15(3):226-30. PubMed ID: 11012098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum CA 19-9 and alpha-fetoprotein levels in primary hepatocellular carcinoma and liver cirrhosis.
    Fabris C; Basso DA; Leandro G; Meggiato T; Elba S; Panozzo MP; Del Favero G; Fogar P; Di Mario F; Naccarato R
    Cancer; 1991 Oct; 68(8):1795-8. PubMed ID: 1717126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA.
    Maestranzi S; Przemioslo R; Mitchell H; Sherwood RA
    Ann Clin Biochem; 1998 Jan; 35 ( Pt 1)():99-103. PubMed ID: 9463746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated preoperative serum CA19-9 levels in patients with hepatocellular carcinoma is associated with poor prognosis after resection.
    Chen YL; Chen CH; Hu RH; Ho MC; Jeng YM
    ScientificWorldJournal; 2013; 2013():380797. PubMed ID: 23843733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical localization of CEA, CA19-9 and DU-PAN-2 in hepatitis C virus-infected liver tissues.
    Kitagawa Y; Iwai M; Muramatsu A; Tanaka S; Mori T; Harada Y; Okanoue T; Kashima K
    Histopathology; 2002 May; 40(5):472-9. PubMed ID: 12010368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating intercellular adhesion molecule-1 in patients with hepatocellular carcinoma.
    Soresi M; Cervello M; Lipani G; Carroccio A; Cartabellotta A; Marasà L; Casto C; Virruso L; Montalto G
    Eur J Gastroenterol Hepatol; 1997 Aug; 9(8):805-9. PubMed ID: 9282280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative Carbohydrate Antigen 19-9: Its Neglected Role in Alpha-Fetoprotein-Negative Hepatocellular Carcinoma Patients.
    Lu LH; Zhang YF; Wei W; Shi M; Guo RP
    J Gastrointest Surg; 2017 Dec; 21(12):2025-2032. PubMed ID: 28840443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the albumin-gamma-glutamyltransferase isoenzyme as a diagnostic marker of hepatocellular carcinoma-complicating liver cirrhosis.
    Pompili M; Addolorato G; Pignataro G; Rossi C; Zuppi C; Covino M; Grieco A; Gasbarrini G; Rapaccini GL
    J Gastroenterol Hepatol; 2003 Mar; 18(3):288-95. PubMed ID: 12603529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of preoperative α-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation.
    Wan P; Zhang J; Long X; Li Q; Xu N; Zhang M; Chen X; Han L; Xia Q
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):553-61. PubMed ID: 24589829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential diagnostic performance of contrast-enhanced ultrasound and tumor markers in differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma.
    Huang XW; Huang Y; Chen LD; Wang Z; Yang Z; Liu JY; Xie XY; Lu MD; Shen SL; Wang W
    J Med Ultrason (2001); 2018 Apr; 45(2):231-241. PubMed ID: 29052791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein-X in patients with cirrhosis: its relationship to cholestasis and hypercholesterolemia.
    Sörös P; Böttcher J; Maschek H; Selberg O; Müller MJ
    Hepatology; 1998 Nov; 28(5):1199-205. PubMed ID: 9794902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged bleeding time: a new clinical manifestation of hepatocellular carcinoma?
    Chu CJ; Lee EY; Hwang SJ; Hsu WC; Tsai YT; Lin HC; Li CP; Wang SS; Lee SD
    J Gastroenterol Hepatol; 1997 Aug; 12(8):563-8. PubMed ID: 9304507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. May plasma cholesterol level be considered a neoplastic marker in liver disease from cirrhosis to hepatocellular carcinoma?
    Venturini I; Amedei R; Modonesi G; Cosenza R; Miglioli L; Cioni G; Zeneroli ML
    Ital J Gastroenterol Hepatol; 1999; 31(1):61-5. PubMed ID: 10091105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical values of CA19-9, CA125 and CEA in malignant obstructive jaundice.
    Ng WW; Tong KJ; Tam TN; Lee SD
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):438-46. PubMed ID: 7634181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial changes in serum alpha-fetoprotein prior to detection of hepatocellular carcinoma in liver cirrhosis.
    Kuwahara T; Sakai T; Majima Y; Hirai K; Tanikawa K
    Hepatogastroenterology; 1993 Aug; 40(4):347-51. PubMed ID: 7691701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic value of gamma-glutamyl transpeptidase to alkaline phosphatase ratio combined with gamma-glutamyl transpeptidase to aspartate aminotransferase ratio and alanine aminotransferase to aspartate aminotransferase ratio in alpha-fetoprotein-negative hepatocellular carcinoma.
    Li J; Tao H; Zhang E; Huang Z
    Cancer Med; 2021 Jul; 10(14):4844-4854. PubMed ID: 34145988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal serum tumour markers values do not imply the presence of extra-hepatic malignancies in patients with chronic liver disease.
    Puoti C; Bellis L; Guarisco R
    Dig Liver Dis; 2010 May; 42(5):387. PubMed ID: 19181575
    [No Abstract]   [Full Text] [Related]  

  • 18. The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis.
    Arrieta O; Cacho B; Morales-Espinosa D; Ruelas-Villavicencio A; Flores-Estrada D; Hernández-Pedro N
    BMC Cancer; 2007 Feb; 7():28. PubMed ID: 17288606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tumoral markers in liver cirrhosis and hepatocellular carcinoma].
    Gómez Rubio M; de Cuenca Morón B; Domínguez M
    Gastroenterol Hepatol; 2005 May; 28(5):308. PubMed ID: 15871818
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma.
    Tao LY; Cai L; He XD; Liu W; Qu Q
    Am Surg; 2010 Nov; 76(11):1210-3. PubMed ID: 21140686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.